enGene Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-07-31 was 24.60K shares, a 29.62% decline year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-04-30 was 0.00 shares, a 100.00% decline year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-01-31 was 117.87K shares, a 13233.48% increase year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-10-31 was 912.85K shares, a 32642.14% increase year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.04M shares, a 792.47% increase from fiscal 2024.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 116.75K shares, a 38.87% increase from fiscal 2023.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 84.07K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-07-31 | 24.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-09-08 | 1.06M shares derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-06-15 | 1.07M shares derived: sum of 4 quarters · filed 2026-06-15 |
| 2026-01-31 | 117.87K shares 10-Q · filed 2026-03-09 | 1.16M shares derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-10-31 | 912.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | 1.04M shares 10-K · filed 2025-12-22 |
| 2025-07-31 | 34.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-09-11 | 131.92K shares derived: sum of 4 quarters · filed 2025-09-11 |
| 2025-04-30 | 93.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-06-12 | 153.95K shares derived: sum of 4 quarters · filed 2025-06-12 |
| 2025-01-31 | 884.00 shares 10-Q · filed 2025-03-10 | 117.64K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-10-31 | 2.79K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | 116.75K shares 10-K · filed 2024-12-19 |
| 2024-07-31 | 56.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-09-10 | |
| 2024-04-30 | 56.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-06-14 | |
| 2024-01-31 | 0.00 shares 10-Q · filed 2024-03-11 | |
| 2023-10-31 | 84.07K shares 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |